In a closely watched decision, the New Jersey Supreme Court ruled that higher federal standards of evidence should be applied in product liability litigation, giving a boost to drug makers because so many lawsuits are filed in the state by people who claim they were harmed by medicines.

The ruling came in a long-running case involving a Roche (RHHBY) acne drug that was blamed for causing Crohn’s disease in more than 2,100 lawsuits filed against the drug maker. At issue were scientific studies the company sought to use to defeat the lawsuits, which prompted competing arguments over differing standards for assessing the validity of the studies and, in particular, expert testimony.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy